Transdifferentiation of myoblasts into osteoblasts - possible use for bone therapy
|dc.identifier.citation||Lin, D. and Carnagarin, R. and Dharmarajan, A. and Dass, C. 2017. Transdifferentiation of myoblasts into osteoblasts - possible use for bone therapy. Journal of Pharmacy and Pharmacology. 69 (12): pp. 1661-1671.|
© 2017 Royal Pharmaceutical Society. Objectives: Transdifferentiation is defined as the conversion of one cell type to another and is an ever-expanding field with a growing number of cells found to be capable of such a process. To date, the fact remains that there are limited treatment options for fracture healing, osteoporosis and bone repair post-destruction by bone tumours. Hence, this review focuses on the transdifferentiation of myoblast to osteoblast as a means to further understand the transdifferentiation process and to investigate a potential therapeutic option if successful. Key findings: The potent osteoinductive effects of the bone morphogenetic protein-2 are largely implicated in the transdifferentiation of myoblast to osteoblast. Bone morphogenetic protein-2-induced activation of the Smad1 protein ultimately results in JunB synthesis, the first transcriptional step in myoblast dedifferentiation. The upregulation of the activating protein-1 binding activity triggers the transcription of the runt-related transcription factor 2 gene, a transcription factor that plays a major role in osteoblast differentiation. Summary: This potential transdifferentiation treatment may be utilised for dental implants, fracture healing, osteoporosis and bone repair post-destruction by bone tumours.
|dc.publisher||John Wiley & Sons Ltd.|
|dc.title||Transdifferentiation of myoblasts into osteoblasts - possible use for bone therapy|
|dcterms.source.title||Journal of Pharmacy and Pharmacology|
|curtin.department||School of Biomedical Sciences|
|curtin.accessStatus||Open access via publisher|
Files in this item
There are no files associated with this item.